J&J and Moderna say Vaccine Data is Supportive for Boosters

The FDA provided briefing documents on booster shots for the Moderna and Johnson & Johnson COVID-19 vaccines on Tuesday, ahead of a two-day public meeting of the agency’s advisers that begins on Thursday. Moderna COVID-19 vaccine booster has half the amount of the two-shot vaccination’s initial shots: 50 micrograms of mRNA vs. 100 micrograms. According to the company’s analysis, evidence on immune response and adverse effects seen in participants tested supports using a booster six months or longer after initial immunization in people aged 18 and older.

The business justified the booster by citing a surge in breakthrough infections caused by the delta variant. However, in light of the FDA’s decision last month on Pfizer-booster BioNTech’s application, Moderna requests a booster dosage of their vaccine under the same conditions. That means the booster would be for persons 65 and older, people 18 to 64 who are at high risk for severe COVID-19, and those 18 to 64 who have been exposed to severe COVID-19 in an institutional or vocational setting.

For those with impaired immune systems, the FDA approved a third, full-strength Moderna dose in August. According to a Johnson & Johnson study, a booster dose given to persons aged 18 and above six months or longer after their first vaccination with a single shot has a favorable risk-benefit ratio.

In addition, the company claims that its data support a booster as soon as two months after the first for persons at increased risk of COVID-19. A separate Johnson & Johnson examination of probable vaccination side effects was included in the documents. According to the corporation, over 33.5 million doses of the one-shot vaccination had been provided worldwide as of the end of August, including 14.3 million in the United States.